French group Sanofi and Stanford University to collaborate on research
Reuters
Published May 06, 2021 06:23
PARIS (Reuters) - French healthcare group Sanofi (PA:SASY) has entered into a three-year collaboration deal with leading U.S. university Stanford over developing research projects to focus on autoimmune diseases and inflammatory conditions.
Sanofi, which is also working on projects to tackle COVID-19, and Stanford said in a joint statement on Thursday that Sanofi would provide funding for the research.
"Sanofi's collaboration with Stanford University aims to transform how autoimmune disorders and inflammatory conditions are understood and treated. It will help accelerate our ambitious immunoscience programmes as we advance a rich pipeline of first- and best-in-class medicines across key therapeutic areas to address unmet patient needs," said Frank Nestle, global head of research and chief scientific officer at Sanofi.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.